Short-lived Options

Cardiovascular disease – CVD

#0
killer globally
0 million
deaths annually
0%
of all global deaths

Chronic kidney disease – CKD

0%
of global population affected

Growing prevalence due to CVD
(diabetes, hypertension, obesity)

Accounting for more deaths than breast and prostate cancers combined

Patients who need cardiovascular replacements suffer repeated procedures, complications or take long-term medication, because current treatment options have severe limitations.

This is especially evident in patients who need:

Artificial heart valves
Artificial vessels – coronary bypass grafts
Artificial vessels – hemodialysis access grafts

Natural cardiovascular restoration

Xeltis’ devices naturally evolve into living blood vessels or heart valves, when colonized by patient’s own tissue.

This therapeutic process is called Endogenous Tissue Restoration, or ETR.

Xeltis’ restorative technology is the world’s most advanced polymer-based technology platform for cardiovascular restoration – through ETR.

ETR

Endogenous Tissue Restoration (ETR) is a new therapeutic approach, enabling the patient’s own body to naturally restore a new blood vessel or heart valve.

With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ device, forming a new, natural and fully functional blood vessel or heart valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.

ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.

ETR In Action

Watch ETR video now
01

Xeltis devices work as normal heart valves or blood vessels once implanted.

ENDOGENOUS TISSUE RESTORATION
02

New tissue forms around and inside the device to develop a new, living, heart valve or blood vessel.

NEOTISSUE FORMATION - ENDOGENOUS TISSUE RESTORATION (ETR)
03

Xeltis devices absorb over time, leaving patients with a natural, healthy and functioning heart valve or blood vessel.

FUNCTIONAL RESTORATION - ENDOGENOUS TISSUE RESTORATION (ETR)
No in vitro tissue engineering
No stem cells
No biological agents
No animal tissue
40+ international patent families portfolio protecting Xeltis’ innovative supramolecular polymer platform and its electrospinning methodology for device manufacturing.
Electrospinning supramolecular polymers using electric charge to draw supramolecular polymer solutions into threads that measure a fraction of the diameter of a hair.
Millions of patients with conditions requiring restoration of blood vessels or heart valves potentially addressed with Xeltis cardiovascular technology.